logo
Menu
Innovation Observatory > Reports > Orthopaedics

Results

Drugs

May 2018

Mexiletine for the Symptomatic Treatment of Myotonic Disorders – First Line

Mexiletine is under registration in Europe for the symptomatic treatment of myotonic disorders. It is administered as an oral capsule and it exerts its action by reducing the rate of contraction in the heart and other muscles. Currently it is used unlicensed in the UK, meaning that it is not currently approved but some healthcare providers consider it to be potentially beneficial based on research or professional experience. There are currently no licensed treatment options available to treat symptoms of myotonia, therefore, if licensed, mexiletine will offer access to an approved treatment option.

Drugs

April 2018

Anakinra for Still’s disease

Anakinra is a drug which blocks a particular inflammatory protein which causes inflammation and is thought to play a role in the activity of Still’s disease. Anakinra is administered by injection under the skin (subcutaneously) and can be used in new onset patients or those with continued disease activity. As of February 2018, anakinra has been licenced for the treatment of adults, adolescents, children and infants aged 8 months and older patients with Still’s disease who have not responded to treatment with NSAIDs or steroids, and therefore require further treatment to control their disease.

Drugs

March 2018

Rigerimod plus Standard of Care for Systemic Lupus Erythematosus

ystemic lupus erythematosus (SLE) is a long-term condition causing inflammation to the joints, skin and other organs. Symptoms presented are usually very general, including fever, joint pain and skin rash but can progress to the most severe, e.g. kidney failure. SLE typically has patterns of flare-ups where the condition gets worse for a period of time. The disease is likely to be caused by a combination of genetic and lifestyle factors and most commonly affects middle-aged women and those of African-Caribbean ethnicity.

Drugs

November 2017

Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

There is currently no cure for systemic sclerosis and treatment options focus on the management of symptoms. Tocilizumab is intended for the treatment of systemic sclerosis in adults. It is currently in development and early research indicates that it is able to target the key mechanisms thought to be responsible for the disease. If licensed, …

Drugs

November 2017

Subcutaneous Tocilizumab (RoACTEMRA) With or Without Methotrexate for the Treatment of Inadequate Responders in Systemic Juvenile Idiopathic Arthritis

Tocilizumab is a drug that targets and blocks the IL-6 pathway and is currently used for the treatment of many diseases, including sJIA, rheumatoid arthritis and Giant Cell Arteritis (GCA). It is now being developed for patients with sJIA that may have been treated with, and have not responded to another drug called methotrexate.

Drugs

November 2017

Tonogenchoncel-L (Invossa) Gene Therapy for Regeneration of Cartilage in Patients with Degenerative Arthritis or Osteoarthritis of the Knee

Tonogenchoncel-L is a type of treatment which involves taking cells which make up the cartilage and altering them genetically to help stimulate the growth of the cartilage.

Get Alerts